Insider Selling: Edwards Lifesciences Corporation (NYSE:EW) Insider Sells 8,950 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the sale, the insider now directly owns 206,900 shares of the company’s stock, valued at $15,565,087. This represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Edwards Lifesciences Trading Down 2.0%

Shares of EW opened at $73.31 on Wednesday. Edwards Lifesciences Corporation has a 12-month low of $58.93 and a 12-month high of $95.25. The company has a quick ratio of 3.66, a current ratio of 4.45 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $43.00 billion, a price-to-earnings ratio of 10.47, a P/E/G ratio of 3.77 and a beta of 1.12. The stock’s 50-day moving average price is $74.77 and its 200 day moving average price is $72.96.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The firm had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period in the previous year, the company posted $0.66 earnings per share. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently modified their holdings of the stock. Prosperity Consulting Group LLC grew its position in Edwards Lifesciences by 3.6% during the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company’s stock worth $289,000 after acquiring an additional 134 shares during the last quarter. Arlington Trust Co LLC lifted its stake in shares of Edwards Lifesciences by 1.2% in the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock valued at $804,000 after purchasing an additional 135 shares during the period. Abacus Planning Group Inc. lifted its stake in shares of Edwards Lifesciences by 0.3% in the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after purchasing an additional 140 shares during the period. Valeo Financial Advisors LLC lifted its stake in shares of Edwards Lifesciences by 2.8% in the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock valued at $372,000 after purchasing an additional 142 shares during the period. Finally, Versant Capital Management Inc lifted its stake in shares of Edwards Lifesciences by 9.3% in the 1st quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company’s stock valued at $123,000 after purchasing an additional 145 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on EW shares. Piper Sandler boosted their price target on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 13th. Truist Financial reduced their price target on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a research report on Friday, April 11th. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Friday, May 16th. Canaccord Genuity Group boosted their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a research report on Friday, April 25th. Finally, Robert W. Baird boosted their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a “neutral” rating in a research report on Thursday, April 24th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $80.20.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.